Pub. Date : 2014 Jul 15
PMID : 24646773
10 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Elevated urinary CCL2: Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months. | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 2 | BACKGROUND: We have demonstrated that 6-month urinary CCL2: Cr is a predictor of interstitial fibrosis and tubular atrophy (IFTA) on 24-month biopsy and death-censored graft loss. | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 3 | As early CCL2: Cr predicts late graft loss, the goal of this study was to determine if 6-month urinary CCL2: Cr was a predictor of IF+i at 24 months. | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 4 | RESULTS: Six-month urinary CCL2: Cr was significantly higher in IF+i and transplant glomerulopathy patients compared with normal histology at 24 months. | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 5 | By multivariate analysis, 6-month urinary CCL2: Cr was independently correlated with IF+i at 24 months (OR 2.78, 95% CI 1.38-6.12, AUC 0.695, P=0.003). | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 6 | Six-month urinary CCL2: Cr was also an independent correlate of 6-month IF+i (OR 1.99, 95% CI 1.03-4.18, AUC 0.63, P=0.04). | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 7 | Six-month urinary CCL2: Cr distinguished noninflamed renal tissue (normal, fibrosis) from IF+i with a sensitivity/specificity of 0.71/0.62 at a cutoff of 15 ng CCL2/mmol Cr (AUC 0.695, P=0.003, n=91). | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 8 | Six-month urinary CCL2: Cr distinguished noninflamed renal tissue (normal, fibrosis) from IF+i with a sensitivity/specificity of 0.71/0.62 at a cutoff of 15 ng CCL2/mmol Cr (AUC 0.695, P=0.003, n=91). | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 9 | CONCLUSIONS: Urinary CCL2: Cr may be useful for the noninvasive identification of patients with or at risk for IF+i. | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |
| 10 | Furthermore, urinary CCL2: Cr may also identify individuals who may benefit from novel interventional trials targeting IF+i. | Chromium | C-C motif chemokine ligand 2 | Homo sapiens |